Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17909313 | 0.91 | NAAA (0.55) | NAAASMN1; SMN2EPHX1HTTCYP2C19 | |
| SCHEMBL17909703 | 0.87 | NAAA (0.64) | NAAASMN1; SMN2EPHX1HTTCYP2C19 | |
| SCHEMBL17909590 | 0.87 | NAAA (0.64) | NAAASMN1; SMN2EPHX1HTTCYP2C19 | |
| SCHEMBL17909131 | 0.87 | NAAA (0.64) | NAAASMN1; SMN2EPHX1HTTCYP2C19 | |
| SCHEMBL20210663 | 0.84 | NAAA (0.68) | NAAASMN1; SMN2EPHX1HTTCYP2C19 | |
| SCHEMBL28144201 | 0.84 | NAAA (0.68) | NAAASMN1; SMN2EPHX1HTTCYP2C19 | |
| SCHEMBL3820123 | 0.84 | NAAA (0.68) | NAAASMN1; SMN2EPHX1HTTCYP2C19 | |
| SCHEMBL17909326 | 0.83 | NAAA (0.55) | NAAASMN1; SMN2EPHX1HTTCYP2C19 | |
| SCHEMBL17909694 | 0.83 | NAAA (0.55) | NAAASMN1; SMN2EPHX1HTTCYP2C19 | |
| SCHEMBL17909519 | 0.83 | NAAA (0.55) | NAAASMN1; SMN2EPHX1HTTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3048093-B1 | ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF | MORESCO CORP (JP) | 2019-02-20 | — | — | EP | disclosed |
| US-10077229-B2 | Ether-containing monoester compound and use thereof | MORESCO CORPORATION (JP) | 2018-09-18 | — | — | US | disclosed |
| EP-3048093-A1 | ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF | Moresco Corporation (JP) | 2016-07-27 | — | — | EP | disclosed |
| US-20160200998-A1 | ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF | MORESCO CORPORATION (JP) | 2016-07-14 | — | — | US | disclosed |
| CN-105579431-A | Ether-containing monoester compound and use thereof | MORESCO CORP | 2016-05-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077229-B2 | Ether-containing monoester compound and use thereof | SFN, CCNE2, HSD3B2 | NAAA 4428/4885SMN1; SMN2 1830/4885EPHX1 626/4885 |
| US-20160200998-A1 | ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF | SFN, CCNE2, MSMO1 | NAAA 4362/4885SMN1; SMN2 1877/4885EPHX1 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.